LondonJun 3 – 6EHA2026
StockholmJun 11 – 14BIO 2026
San DiegoJun 16 – 19ENDO 2026BostonJun 18 – 21ADA 2026San FranciscoJun 19 – 22ESC 2026
LisbonAug 28 – Sep 1EASD 2026
MadridSep 9 – 12ERS 2026
CopenhagenSep 12 – 15ESMO 2026
BerlinSep 12 – 16ECTRIMS 2026BarcelonaSep 17 – 20UEG Week 2026
ViennaOct 3 – 7AHA 2026ChicagoNov 7 – 9ACR 2026Washington DCNov 14 – 19ASH 2026New OrleansDec 12 – 15ACC.27 Together With WCCHoustonApr 10 – 12PastEASL Congress 2026BarcelonaMay 27 – 30PastATS 2026OrlandoMay 15 – 20PastDDW 2026ChicagoMay 2 – 5PastAAN 2026PhiladelphiaApr 25 – May 2PastAACR 2026San DiegoApr 17 – 22EULAR 2026LondonJun 3 – 6EHA2026StockholmJun 11 – 14BIO 2026San DiegoJun 16 – 19ENDO 2026BostonJun 18 – 21ADA 2026San FranciscoJun 19 – 22ESC 2026LisbonAug 28 – Sep 1EASD 2026MadridSep 9 – 12ERS 2026CopenhagenSep 12 – 15ESMO 2026BerlinSep 12 – 16ECTRIMS 2026BarcelonaSep 17 – 20UEG Week 2026ViennaOct 3 – 7AHA 2026ChicagoNov 7 – 9ACR 2026Washington DCNov 14 – 19ASH 2026New OrleansDec 12 – 15ACC.27 Together With WCCHoustonApr 10 – 12PastEASL Congress 2026BarcelonaMay 27 – 30PastATS 2026OrlandoMay 15 – 20PastDDW 2026ChicagoMay 2 – 5PastAAN 2026PhiladelphiaApr 25 – May 2PastAACR 2026San DiegoApr 17 – 22
The Life Science Feed
Podcast
Deep dives with clinicians, researchers, and industry leaders.
All episodes
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
The ASCO 2026 June 1st program focused on advancements in immunotherapy, particularly for solid tumours, with new data presented on combination strategies.
Amyloid Therapies Show Limited Cognitive Benefit in Alzheimer's
Amyloid-beta targeting therapies for Alzheimer's disease demonstrate modest effects on cognitive decline, with clinical significance remaining uncertain.
Myasthenia Gravis in Pregnancy: Exacerbations Common in Peripartum
Myasthenia gravis (MG) in pregnancy presents diagnostic and management challenges, with exacerbations common in the first trimester and postpartum period.
COVID Not Primary Driver of Pediatric Type 1 Diabetes Rise
Evidence suggests the observed increase in pediatric type 1 diabetes predates the COVID-19 pandemic, indicating other factors are at play.
CAR T-Cell Therapy Shows Efficacy in Refractory Autoimmune Disease
CAR T-cell therapy, traditionally for cancer, demonstrates potential in severe autoimmune conditions, offering a new therapeutic avenue.
Biologics Offer Targeted Efficacy in Psoriasis Management
Biologic therapies have significantly advanced psoriasis treatment by targeting specific immune pathways, offering improved outcomes for patients.
Antihypertensive Use Linked to Higher Fall Risk Across Patient Groups
Antihypertensive medications are associated with an increased fall risk across various patient demographics, necessitating careful risk-benefit assessment.
Alternaria Allergy in Youth Signals Persistent Asthma Risk
Early sensitization to Alternaria alternata in children and adolescents is a significant predictor of asthma persistence into adulthood.
Stay ahead in
Life Science.
CAR-T Therapy Versus Bispecific Antibodies
The next phase of CAR-T addresses its biggest limitations: off-the-shelf allogeneic products, in vivo gene delivery, and bispecific antibodies that redirect T cells without any gene engineering. Sarah Mitchell and James Carter explore where the technology is going - and what blood cancer management looks like by 2030.
Small Molecules VS CAR-T In CLL
By the time CAR-T arrived in CLL, the disease had already been transformed by BTK inhibitors and venetoclax. TRANSCEND CLL 004 showed 18% CR in BTKi/venetoclax-refractory disease. Sarah Mitchell and James Carter explore why CLL is harder for CAR-T, where it still has a role - especially in Richter's transformation - and why timing of T cell collection matters.
Moving CAR-T To Earlier Myeloma Lines
Ciltacabtagene autoleucel achieved a 97% overall response rate and 67% complete response in triple-class refractory multiple myeloma - numbers not thought achievable a decade ago. CARTITUDE-4 has now moved it to the second line. Sarah Mitchell and James Carter cover the BCMA story, the new targets, and the resistance mechanisms driving the next generation.
CAR-T Masterstroke Or Biological Chaos?
1 min readDoctor-Patient Communication Improves Treatment Acceptance in Cancer
6 min readTile Radiation for Large Brain Mets: A New Approach at ASCO 2026
6 min readMore Breast Cancer Patients Can Skip Axillary Dissection
6 min readHYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
6 min readOncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
6 min read
Alcohol and Sugar: A Dual Metabolic Challenge for Patients
Patients consuming alcohol and high-sugar diets face a compounded metabolic risk, impacting liver function and glucose regulation. Clinicians must address both factors.
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
EASL Congress 2026 will feature pivotal trials in NAFLD/NASH, HBV, and HCC, potentially reshaping current treatment paradigms.
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
6 min readEASL 2026 Forum: Enhancing Patient-Clinician Communication
6 min readEASL 2026: Alcohol Policy Action Needed for Liver Disease
6 min readA-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
6 min readMASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
5 min readEASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
7 min read
Managing Acute Heart Failure And Cardiogenic Shock
Acute decompensated heart failure drives over one million hospital admissions annually. 30-day readmission rates are 25%. When the heart cannot compensate, the tools change entirely - IV diuretics, inotropes, mechanical circulatory support. Sarah Mitchell and James Carter cover ADHF management, cardiogenic shock, and how to prevent the revolving door.
Semaglutide For Obese Heart Failure Patients
More than 80% of HFpEF patients are overweight or obese. STEP-HFpEF showed semaglutide 2.4mg improved symptoms by 16 points on the KCCQ and reduced weight by 13.3% - now a Class IIa ESC recommendation. Sarah Mitchell and James Carter explore why treating the metabolic environment is the new paradigm for HFpEF.
Diabetes Drugs For Stiff Heart Failure
Heart failure with preserved ejection fraction accounts for more than half of all HF diagnoses. For two decades every major drug trial failed. Then SGLT2 inhibitors changed everything - twice. Sarah Mitchell and James Carter explain why HFpEF was so hard, and what finally worked.
How Four Drugs Beat Heart Failure
1 min readTricuspid Valve Surgery Benefits Adults with Systemic Right Ventricle
6 min readDual Plane Block May Cut Opioid Use After Bypass Surgery
6 min readPAHO's HEARTS 2.0 Outlines 38-Step Pathway for Cardio-Renal Care
6 min readRight Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
7 min readPrimary LV Unloading in Anterior STEMI Shows No Benefit in STEMI-Door to Unload Trial
6 min read
2026 Dyslipidemia Guideline: Utility in Family Medicine Assessed
A new assessment tool, G-TRUST, evaluates the relevance and trustworthiness of cardiovascular risk guidelines, including statin recommendations.
The GLP-1 Muscle Loss Dilemma
GLP-1 receptor agonists drive significant lean mass loss alongside fat loss — a concern that may undermine long-term metabolic health and physical function. Sarah Mitchell and James Carter examine the muscle loss evidence, the role of resistance training, and emerging strategies to preserve lean tissue during weight loss.
The Velvet Rope Of Weight Loss Drugs
Semaglutide and tirzepatide produce results that obesity medicine has never seen before — but demand vastly outstrips supply, cost remains prohibitive for many, and prescribing criteria vary widely between health systems. Sarah Mitchell and James Carter examine who is getting GLP-1 therapy and why equity matters.
GLP-1 Drugs Protect Hearts And Kidneys
1 min readRewiring The Brain To Silence Food Noise
1 min readCOVID Not Primary Driver of Pediatric Type 1 Diabetes Rise
6 min readTirzepatide: Efficacy in Weight Management Explored at ATS 2026
6 min readLower-Dose Tirzepatide: Can It Sustain Weight Loss Long-Term?
7 min readOral Orforglipron Sustains Weight Loss After Injectable GLP-1 Therapy
6 min read
Reassuring Data for High-Efficacy MS Meds in Pregnancy
New data provide reassurance regarding the use of high-efficacy multiple sclerosis therapies during pregnancy, addressing a significant clinical dilemma.
Amyloid Therapies Show Limited Cognitive Benefit in Alzheimer's
Amyloid-beta targeting therapies for Alzheimer's disease demonstrate modest effects on cognitive decline, with clinical significance remaining uncertain.
CGRP Inhibitors for Migraine: CV Safety Data Limited in High-Risk Patients
CGRP-targeted therapies are effective for migraine prevention, but cardiovascular safety data is limited in patients with established vascular disease.
Amyloid Therapies Show Limited Cognitive Benefit in AD
4 min readPARP1 Deficiency Reduces Amyloid Pathology in Familial AD Model
6 min readBrain Cooling After Thrombectomy: Does Hypothermia Aid LVO Recovery?
6 min readGut Microbiota Signal the Brain via the Vagus Nerve: What GPs Should Know
7 min readLow-Dose Lithium for Cognitive Decline: What the Evidence Actually Shows
7 min readParkinson's Neuroprotection 2025: Three Strategies Under Review
5 min read
